Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: MR Martin Vu

Back to Search
Vu M, Degeling K, Westerman D ( 2024 ) . Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients . Journal of Cancer Policy vol. 41 ,
Vu M, Degeling K, Ryland GL, Hofmann O, Ng AP, IJzerman MJ ( 2024 ) . Economic Impact of Whole Genome Sequencing and Whole Transcriptome Sequencing Versus Routine Diagnostic Molecular Testing to Stratify Patients with B-Cell Acute Lymphoblastic Leukemia . Journal of Molecular Diagnostics vol. 26 , ( 8 ) 673 - 684 .
Vu M, Degeling K, Thompson ER, Blombery P ( 2023 ) . Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia . Applied Health Economics and Health Policy vol. 22 , ( 1 ) 107 - 122 .
Fagery M, Khorshidi HA, Wong SQ ( 2023 ) . Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review . PharmacoEconomics vol. 41 , ( 10 ) 1229 - 1248 .
Vu M, Degeling K, Thompson ER, Westerman D ( 2022 ) . Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review . European Journal Of Haematology vol. 108 , ( 6 ) 469 - 485 .
Vu M, Carvalho N, Clarke PM, Buchbinder R ( 2020 ) . Impact of Comorbid Conditions on Healthcare Expenditure and Work-related Outcomes in Patients With Rheumatoid Arthritis . The Journal of Rheumatology vol. 48 , ( 8 ) 1221 - 1229 .
Vu M, Degeling K, Martyn M, Lynch E, Chong B, Gaff C ( 2020 ) . Evaluating the resource implications of different service delivery models for offering additional genomic findings . Genetics in Medicine vol. 23 , ( 4 ) 606 - 613 .
Degeling K, Vu M, Koffijberg H, Wong H-L, Koopman M ( 2020 ) . Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review . PharmacoEconomics vol. 38 , ( 7 ) 683 - 713 .
Lewis C, Beecham E, Boardman F, Brady G, Buchanan J, Clark S, Gilchrist K, Hardelid P et al. . Exploring the feasibility, acceptability and impact of genomic newborn screening for rare diseases in England: A study protocol for the Generation Study - Process and Impact Evaluation .
Smith H, Vu M, Dangouloff T, Schubert C, Level C, Lamsal R, Christensen K, Stark Z et al. . Health Economic Evaluations of Genomic Newborn Screening: Approaches by studies within the International Consortium on Newborn Sequencing .
Vu M, Clark SE, Gilchrist K, Boardman F, Vindrola-Padros C, Lewis C, Melissa H, Buchanan J . The Costs of Genomic Newborn Screening in England: A Micro-Costing Analysis from the Generation Study . Genetics in Medicine
Back to Search